research use only

DAPT γ-Secretase inhibitor

Name: DAPT
Brand: Selleck Chemicals
SKU: S2215
Availability: InStock
Rating: 5 (399 reviews)

Cat.No.S2215

DAPT is a novel γ-secretase inhibitor, which inhibits Aβ production with IC50 of 20 nM in HEK 293 cells. DAPT enhances the apoptosis of human tongue carcinoma cells and regulates autophagy.

Chemical Structure

Molecular Weight: 432.46

Jump to Mechanism of Action Cell Culture & Working Concentration Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: Purity: 99.99%

99.99

Products Often Used Together with DAPT

GI254023X

This compound and GI254023X block NOTCH activation in PC3 cells co-cultured with OP9-DLL1/OP9 cells.

SU5402

This compound and SU5402, along with other small molecule inhibitors, accelerate the derivation of functional, early-born cortical neurons from human pluripotent stem cells (hPSCs).

SB431542

This compound and SB431542, along with other small molecules, efficiently reprogram cultured human fetal astrocytes into functional neurons.

Y-27632 Dihydrochloride

This compound and Y-27632 2HCl, along with other small molecule compounds, are used for In vitro stimulation of muller (MCs)/TR-MUL5 cells.

Related Targets	HDAC Caspase MMP HCV Protease Cysteine Protease DPP Tyrosinase HIV Protease Proteasome Serine Protease PCSK9 Glutaminase Acyltransferase Thrombin Cathepsin B MALT PAD PREP Neprilysin SGK Aminopeptidase 3C-Like Protease PGDS GOT
Related Products	RO4929097 (RG-4733) DBZ (Dibenzazepine) LY411575 Avagacestat (BMS-708163) MK-0752 Semagacestat (LY450139) Nirogacestat (PF-03084014) MDL-28170 L-685,458

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Function assay	THP1				Displacement of [3H]IN973 from gamma-secretase in human THP1 cells, acvalue.	17932033
GC-B	Growth Inhibition Assay	6.25-100 μM	24 h	DMSO	inhibits the cell growth in a dose-dependent manner	19542446
U87	Function Assay	2 μM	48 h	DMSO	blocks t-AUCB-induced activation of the p38 MAPK/MAPKAPK2/Hsp27 pathway and inhibits expression of NICD1	24793313
A549	Growth Inhibition Assay	10 μM	24h		decreases the cell viability combined with PTE	23671619
U87	Growth Inhibition Assay	2 μM	48 h	DMSO	strengthens t-AUCB-induced cell growth suppression	24793313
U251	Function Assay	2 μM	48 h	DMSO	blocks t-AUCB-induced activation of the p38 MAPK/MAPKAPK2/Hsp27 pathway and inhibits expression of NICD1	24793313
U251	Growth Inhibition Assay	2 μM	48 h	DMSO	strengthens t-AUCB-induced cell growth suppression	24793313
Saos-2	Function Assay	100 μM	24 h	DMSO	desensitizes the cell line to cisplatin treatment	24894297
MG63	Function Assay	100 μM	24 h	DMSO	desensitizes the cell line to cisplatin treatment	24894297
SHG-44	Growth Inhibition Assay	0.5-10 μM	1-5 d		inhibits the cell viability at the optimal concentration of 1 μM	25063285
A549 CD133−	Growth Inhibition Assay	2 μM	48 h		enhances cell growth inhibition induced by CDDP	24502949
A549 CD133+	Growth Inhibition Assay	2 μM	48 h		enhances cell growth inhibition induced by CDDP	24502949
HT29	Growth Inhibition Assay	0.5-75 μM	12/24/48 h	DMSO	inhibits the cell growth in a concentration manner	25257945
Cytotoxicity assay	SNU475		72 hrs		Cytotoxicity against human SNU475 cells assessed as growth inhibition after 72 hrs by SRB assay, Displacement of [3H]IN973 from gamma-secretase in human THP1 cells, acvalue..	ChEMBL
Cytotoxicity assay	HuH7		72 hrs		Cytotoxicity against human HuH7 cells assessed as growth inhibition after 72 hrs by SRB assay, Cytotoxicity against human SNU475 cells assessed as growth inhibition after 72 hrs by SRB assay, Displacement of [3H]IN973 from gamma-secretase in human THP1 cells, acvalue...	ChEMBL
Cytotoxicity assay	Hep3B		72 hrs		Cytotoxicity against human Hep3B cells assessed as growth inhibition after 72 hrs by SRB assay, Cytotoxicity against human HuH7 cells assessed as growth inhibition after 72 hrs by SRB assay, Cytotoxicity against human SNU475 cells assessed as growth inhibition after 72 hrs by SRB assay, Displacement of [3H]IN973 from gamma-secretase in human THP1 cells, acvalue....	ChEMBL
Cytotoxicity assay	Mahlavu		72 hrs		Cytotoxicity against human Mahlavu cells assessed as growth inhibition after 72 hrs by SRB assay, Cytotoxicity against human Hep3B cells assessed as growth inhibition after 72 hrs by SRB assay, Cytotoxicity against human HuH7 cells assessed as growth inhibition after 72 hrs by SRB assay, Cytotoxicity against human SNU475 cells assessed as growth inhibition after 72 hrs by SRB assay, Displacement of [3H]IN973 from gamma-secretase in human THP1 cells, acvalue.....	ChEMBL
Click to View More Cell Line Experimental Data

Chemical Information, Storage & Stability

Molecular Weight	432.46	Formula	C₂₃H₂₆F₂N₂O₄	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	208255-80-5	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	GSI-IX, LY-374973			Smiles	CC(C(=O)NC(C1=CC=CC=C1)C(=O)OC(C)(C)C)NC(=O)CC2=CC(=CC(=C2)F)F

Solubility

In vitro
Batch:

DMSO : 86 mg/mL ( (198.86 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 41 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.550mg/ml (1.27mM)	Taking the 1 mL working solution as an example, add 50 μL of 11 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to make it clear; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG 300 2 5%Tween80 3 50% ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	2.000mg/ml (4.62mM)	Taking the 1 mL working solution as an example, add 50 μL of 40 mg/mL clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify; add 50 μL of Tween-80 to the above system, mix evenly to clarify; Then continue to add 500 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	Notch ^[1] Aβ ^[1] (HEK 293 cells) 20 nM
In vitro	In human primary neuronal cultures, DAPT also shows inhibitory effects on Aβ production with IC50 of 115 nM and 200 nM respectively for Aβ total and Aβ42, which is 5-10-fold lower than is observed in HEK 293 cells. ^[1] A recent study shows that this compound inhibits the proliferation of SK-MES-1 cells in a concentration-dependent manner with IC50 of 11.3 μM. In addition, it also induces caspase-dependent and caspase-independent apoptosis in lung squamous cell carcinoma cells by inhibiting Notch receptor signaling pathway. ^[2]
Kinase Assay	In vitro Aβ reduction assays
Kinase Assay	Human embryonic kidney cells (American Type Culture Collection CRL-1573), transfected with the gene for APP751 (HEK 293) are used for routine Aβ reduction assays. Cells are plated in 96-well plates and allowed to adhere overnight in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum. DAPT are diluted from stock solutions in dimethylsulfoxide (DMSO) to yield a final concentration equal to 0.1% DMSO in media. Cells are pre-treated for 2 hours at 37 °C with this compound, media are aspirated off and fresh compound solutions applied. After an additional 2-hour treatment period, conditioned media is drawn off and analyzed by a sandwich ELISA (266–3D6) specific for total Aβ. Reduction of Aβ production is measured relative to control cells treated with 0.1% DMSO and expressed as a percentage inhibition. Data from at least six doses in duplicate are fitted to a four-parameter logistical model using XLfit software in order to determine potency. Human and PDAPP mouse neuronal cultures are grown in serum-free media to enhance their neuronal characteristics, and appeared to be greater than 90% neurons after maturation prior to use. Conditioned media to establish baseline Aβ values are collected by adding fresh media to each well and incubated for 24 hours at 37 °C in the absence of this chemical. Cultures are then treated with fresh media containing this compound at the desired range of concentrations for an additional 24 hours at 37 °C, and conditioned media collected. For the measurement of total Aβ, samples are analyzed with the same ELISA (266–3D6) as used for the HEK 293 cell assays. Analyses of samples for Aβ42 production are performed by a separate ELISA (21F12–3D6) that utilizes a capture antibody specific for the Aβ42 C-terminus. Inhibition of production for both total Aβ and Aβ42 are determined by the difference between the values for the compound treatment and baseline periods. After plotting percentage inhibition versus this compound concentration, data are analyzed with XLfit software, as above, to determine potency.
In vivo	DAPT administration (100mg/kg) leads to a robust and sustained pharmacodynamic effect in PDAPP mice that this compound levels in the brain exceeds 100 ng/g within 1 hour and persists up to 18 hours after administration, with peak levels of 490 ng/g observed after 3 hour. And during the period, this chemical (100 mg/kg) also reduces the cortical total Aβ and Aβ42 in a dose-dependent manner with a 50% reduction. ^[1] In rat cerebral cortexes, this compound (40 mg/kg) suppresses the LPS-induced activity of γ-secretase and increases the cell apoptosis with the prolonged neuroinflammation. ^[3]
References	https://pubmed.ncbi.nlm.nih.gov/11145990/ https://pubmed.ncbi.nlm.nih.gov/22583356/ https://pubmed.ncbi.nlm.nih.gov/22445932/

Applications

Methods	Biomarkers	PMID
Western blot	Snail / N-cadherin / Vimentin / E-cadherin Bax / caspase-3 / Bcl-2 NICD / Pax7 / Pax3 / MyoD / Myogenin / p21	24932308
Growth inhibition assay	Cell viability	27118928
Immunofluorescence	CDK5	18662245

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06292117	Recruiting	Ischemic Stroke\|CYP2C19 Polymorphism	University of Virginia\|American Heart Association	April 16 2024	--
NCT06074549	Recruiting	Coronary Artery Disease	Elixir Medical Corporation	March 10 2024	--
NCT06223607	Recruiting	Baseline Thrombocytopenia	Methodist Health System	August 22 2022	--

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I would like to ask if you would recommend it used in endothelial cells (e.g. both murine and human endothelial cells).

Answer:
I think this compound can be used in endothelial cells from both human and mouse, please see the following reference: http://www.ncbi.nlm.nih.gov/pubmed/19481797; http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2615564/

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):